Results 181 to 190 of about 68,288 (264)
Targeting Genome Maintenance Defects of Cancers Using Chain‐Terminating Nucleoside Analogs
Nucleoside analogs interfere with DNA replication either by their chain‐terminating properties or by serving as DNA damage on the template. The genome maintenance pathways required to maintain cellular tolerance to each nucleoside analog vary depending on the drug.
Ryotaro Kawasumi +2 more
wiley +1 more source
Frequency of Founder Mutations in <i>BRCA1</i> and <i>BRCA2</i> Genes in Hereditary Breast Cancers in Poland vs. Other Countries. [PDF]
Kulikowska B, Panasiuk B, Posmyk R.
europepmc +1 more source
Whole‐exome sequencing of five families with non‐medullary thyroid cancer revealed three candidate genes. Functional analyses confirmed BCL2L11 as a strong candidate gene for hereditary predisposition to non‐medullary thyroid cancer. ABSTRACT Familial non‐medullary thyroid cancer, defined as two or more affected first‐degree relatives, accounts for 3 ...
Duygu Abbasoglu +9 more
wiley +1 more source
Invasive Lobular Carcinoma of the Male Breast With BRCA2 Mutation. [PDF]
Abe M +9 more
europepmc +1 more source
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Rohini Roy, Jarin Chun, S. Powell
semanticscholar +1 more source
Assessment of twenty testicular AGCTs with two different next‐generation sequencing (NGS) panels reveals differences with ovarian AGCTs, including absence of hotspot FOXL2 variants. Aims Testicular adult granulosa cell tumours (AGCTs) are rare and show several clinical–pathological differences with their ovarian counterparts.
Costantino Ricci +20 more
wiley +1 more source
Updated analysis of pathogenic variants in BRCA1/BRCA2 among the general Japanese population. [PDF]
Mariya T +5 more
europepmc +1 more source
ABSTRACT Background Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive cancers, typically diagnosed at an advanced stage due to its subtle and often absent early symptoms. Despite representing only 3% of new cancer cases, it is projected to become the second leading cause of cancer‐related deaths by 2030.
Muhammad Masroor Hussain +5 more
wiley +1 more source

